RNS
Reach - non-regulatory announcement
25 February
2025
Solvonis Therapeutics plc
("Solvonis Therapeutics" or the "Company")
Solvonis Therapeutics -
Advancing Treatments for Mental Health and
Addiction
Solvonis Therapeutics (LSE:
SVNS), an innovative biotechnology company
co-developing therapeutics for mental health
disorders, announces that Anthony Tennyson, Chief Executive
Officer of the Company, will be presenting Solvonis Therapeutics
plc in the Strategy and Growth track
at the PharmaSynergyRx 2025 event in London on 27
February 2025.
PharmaSynergyRx brings together over
200 Business Development and C-suite executives, creating a
platform for companies pursuing co-developments, partnerships,
licensing and commercial deals within the bio-technology
industry.
For more information, please
visit: https://pharma-synergy-conference.com/pharmasynergy-2025/
Enquiries:
Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
Email: anthony@solvonis.com
Allenby Capital (Financial Adviser and Broker)
+44 (0) 20 3328 5656
Nick Naylor
/ Liz Kirchner (Corporate Finance) | Guy McDougall
(Sales)
About Solvonis Therapeutics plc
Solvonis Therapeutics plc is an
innovative biotechnology company focused on developing
intellectual property related to the
treatment of mental health and substance use disorders, and
co-developing therapeutics for mental health disorders. Solvonis'
mission is to improve outcomes for individuals suffering from
mental health disorders, with an initial focus on trauma-related
mental health conditions, such as PTSD. PTSD affected approximately
13 million adults in the U.S. in 2020, with the Company estimating
a current affected population of 20 million across the U.S., UK,
and key EU markets.
www.solvonis.com | LinkedIn
| X (formerly
Twitter)
About Reach announcements
This is an RNS Reach announcement.
Reach is an investor communication service aimed at assisting
listed and unlisted (including AIM quoted) companies to distribute
media only / non-regulatory news releases into the public
domain. Information required to be notified under the AIM
Rules for Companies, Market Abuse Regulation or other regulation
would be disseminated as an RNS regulatory announcement and not on
Reach.
